Mirum Pharmaceuticals (MIRM) Stock Analysis

What Mirum Pharmaceuticals does

Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.

Key metrics

ETFs linked to MIRM

Broad-market and Healthcare sector ETFs an investor holding Mirum Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how MIRM fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Mirum Pharmaceuticals?

Mirum Pharmaceuticals trades under the ticker MIRM on NASDAQ.

Which exchange is MIRM listed on?

MIRM is listed on NASDAQ.

What sector does Mirum Pharmaceuticals operate in?

Mirum Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze MIRM in a portfolio?

PortView shows MIRM's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.